Why Is PTC THERAPEUTICS INC (PTCT) Stock Down Today?
By the Top Tier Newswire AI Desk · July 31, 2026 at 10:38 AM ET · reviewed against 3 wire stories
PTC THERAPEUTICS INC (PTCT) is down -8.74% in the latest session. Our newswire has captured 3 stories on PTCT across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
PTCT stock is down 8.74% to $68.92 in a session marked by a sharp decline from its opening price. The stock opened with a 0.9% gap down and quickly dropped to a low of $64.57 before trading closed at $68.92. The move follows the company’s second-quarter 2026 earnings report and a corporate update that included a raised sales forecast, but also a leadership change and mixed analyst reactions.
What Happened
PTC Therapeutics reported Q2 2026 results with total revenue of $361 million, including $239 million in product revenue. The company raised its full-year 2026 total revenue guidance to $1.18 billion to $1.28 billion. However, the 8-K filing disclosed the departure of a director and the appointment of certain officers, signaling internal changes. The earnings call, held on July 30, 2026, featured comments from company executives, but the market reacted negatively, with the stock falling sharply during the session. The PR Newswire announcement highlighted the robust Q2 performance, but the broader market response was bearish, as reflected in the intraday price action.
What The Data Shows
The stock opened at $74.85 and fell to $64.57, a level not seen since early August. Volume so far is 0.9 million shares, which is 0.5 times the 3-month daily average. The stock is currently trading within its 52-week range of $43.17 to $90.87. Recent insider transactions include 14 sales totaling $16.6 million in the last 90 days, with the most recent filing on July 16. Congressional trades include two recent purchases by Donald J. Trump in March and February 2026, and a sale in January.
What To Watch
The stock is set to continue trading with elevated volatility. Investors should monitor the company’s upcoming earnings and any further leadership developments. Analyst coverage remains mixed, with Wells Fargo and Cantor Fitzgerald maintaining overweight ratings while RBC Capital maintains a sector perform rating.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
PTCT · Jul 31 session (5-min) · -8.32% vs prior close · updated 8:56 PM ETAI sentiment, last 36h · averaged over 3 stories · 57/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
10d agoSeeking AlphaNEUTRAL 50Earnings
PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript
PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call July 30, 2026 4:30 PM EDTCompany ParticipantsEllen Cavaleri - Head of Investor RelationsMatthew Klein -...
11d agoSEC 8-KNEUTRAL 50General
PTC THERAPEUTICS, INC. (PTCT) files 8-K
Filed: 2026-07-30 AccNo: 0001070081-26-000016 Size: 413 KB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
11d agoPR NewswireBULLISH 71Earnings
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950 million – – Sephience™ (sepiapterin) Q2 2026...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →